Altamira Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
Altamira Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-814.5%
Buyback Yield
| Total Shareholder Yield | -814.5% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Altamira Therapeutics completes enrollment in trial of its nasal spray to treat COVID
Sep 13Altamira Therapeutics moving forward on plans to divest legacy assets, including Bentrio
Aug 30Altamira starts development program for potential arthritis therapy
Jul 25Altamira announces peer-reviewed publication on mRNA delivery platform
Jul 19Altamira gains on peer-reviewed preclinical data publication for its RNA delivery platform
Jul 12Auris Medical shares rise on OligoPhore Lymphoma study results
Jun 21Auris Medical starts preparations for COVID-19 trial with Bentrio in India
Jun 01Auris Medical updates on pollen challenge study for nasal spray
May 10Are Insiders Buying Auris Medical Holding Ltd. (NASDAQ:EARS) Stock?
Dec 09
Auris Medical prices $8M direct equity offering, stock -22%
Dec 02Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if CYTO.F's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CYTO.F's dividend payments have been increasing.
Dividend Yield vs Market
| Altamira Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (CYTO.F) | n/a |
| Market Bottom 25% (US) | 1.5% |
| Market Top 25% (US) | 4.6% |
| Industry Average (Pharmaceuticals) | 2.5% |
| Analyst forecast (CYTO.F) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate CYTO.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CYTO.F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate CYTO.F's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CYTO.F has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 23:51 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Altamira Therapeutics Ltd. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hunter Diamond | Diamond Equity Research LLC |
| Maxim Jacobs | Edison Investment Research |
| Christopher Howerton | Jefferies LLC |